{ "resourceType" : "ConceptMap", "id" : "mii-cm-onko-atc-transitions-2024", "meta" : { "extension" : [{ "url" : "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-license", "valueCode" : "CC-BY-4.0" }, { "extension" : [{ "url" : "packageId", "valueId" : "de.medizininformatikinitiative.kerndatensatz.onkologie" }, { "url" : "version", "valueString" : "2027.0.0-ballot.1" }, { "url" : "uri", "valueUri" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko" }], "url" : "http://hl7.org/fhir/StructureDefinition/package-source" }], "profile" : ["http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-shareableconceptmap", "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-publishableconceptmap"] }, "language" : "de", "text" : { "status" : "generated", "div" : "

German

Generated Narrative: ConceptMap mii-cm-onko-atc-transitions-2024

Profiles: CRMI Shareable ConceptMap, CRMI Publishable ConceptMap

Mapping from MII VS Onkologie Systemische Therapie Substanzen ATC 2023 to MII VS Onkologie Systemische Therapie Substanzen ATC 2024


Mapping from http://fhir.de/CodeSystem/bfarm/atc (Atc) to http://fhir.de/CodeSystem/bfarm/atc (Atc)

Source CodeRelationshipTarget CodeComment
L04AA34 (Alemtuzumab)is equivalent toL04AG06 (Alemtuzumab)Reklassifizierung innerhalb der Immunsuppressiva
L04AA26 (Belimumab)is equivalent toL04AG04 (Belimumab)
L04AA25 (Eculizumab)is equivalent toL04AJ01 (Eculizumab)Reklassifizierung zu Komplement-Inhibitoren
L04AA21 (Efalizumab)is equivalent toL04AG02 (Efalizumab)
L01EG02 (Everolimus)is equivalent toL04AH02 (Everolimus)Zusätzliche Klassifizierung als Immunsuppressivum (behält auch L01EG02)
L04AA27 (Fingolimod)is equivalent toL04AE01 (Fingolimod)Reklassifizierung zu Sphingosin-1-Phosphat-Rezeptor-Modulatoren
L04AA13 (Leflunomid)is equivalent toL04AK01 (Leflunomid)
L01FX24 (Mosunetuzumab)is equivalent toL01FX25 (Mosunetuzumab)Code-Anpassung innerhalb der bispezifischen Antikörper
L04AA02 (Muromonab-CD3)is equivalent toL04AG01 (Muromonab-CD3)
L04AA23 (Natalizumab)is equivalent toL04AG03 (Natalizumab)
L01XY03 (Nivolumab und Relatlimab)is equivalent toL01FY02 (Nivolumab und Relatlimab)Reklassifizierung zu Kombinationen monoklonaler Antikörper
L01FA02 (Ofatumumab)is equivalent toL04AG12 (Ofatumumab)Zusätzliche Klassifizierung als Immunsuppressivum (behält auch L01FA02)
L01XY02 (Pertuzumab und Trastuzumab)is equivalent toL01FY01 (Pertuzumab und Trastuzumab)Reklassifizierung zu Kombinationen monoklonaler Antikörper
L04AA10 (Sirolimus)is equivalent toL04AH01 (Sirolimus)Reklassifizierung zu mTOR-Inhibitoren (Immunsuppressiva)
" }, "extension" : [{ "url" : "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability", "valueCode" : "shareable" }, { "url" : "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability", "valueCode" : "publishable" }, { "url" : "http://hl7.org/fhir/StructureDefinition/artifact-versionPolicy", "valueCodeableConcept" : { "coding" : [{ "system" : "http://terminology.hl7.org/CodeSystem/artifact-version-policy-codes", "code" : "package", "display" : "Package" }] } }, { "url" : "http://hl7.org/fhir/StructureDefinition/resource-approvalDate", "valueDate" : "2026-09-15" }, { "url" : "http://hl7.org/fhir/StructureDefinition/artifact-topic", "valueCodeableConcept" : { "coding" : [{ "system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "code" : "C3262" }] } }, { "url" : "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail" : { "telecom" : [{ "system" : "email", "value" : "thomas.debertshaeuser@charite.de" }] } }, { "url" : "http://hl7.org/fhir/StructureDefinition/artifact-editor", "valueContactDetail" : { "name" : "Taskforce Core Data Set" } }, { "url" : "http://hl7.org/fhir/StructureDefinition/artifact-reviewer", "valueContactDetail" : { "name" : "Interoperability Working Group", "telecom" : [{ "system" : "url", "value" : "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group" }] } }, { "url" : "http://hl7.org/fhir/StructureDefinition/artifact-reviewer", "valueContactDetail" : { "name" : "National Steering Committee", "telecom" : [{ "system" : "url", "value" : "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee" }] } }, { "url" : "http://hl7.org/fhir/StructureDefinition/artifact-endorser", "valueContactDetail" : { "name" : "Interoperability Working Group", "telecom" : [{ "system" : "url", "value" : "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group" }] } }, { "url" : "http://hl7.org/fhir/StructureDefinition/artifact-endorser", "valueContactDetail" : { "name" : "National Steering Committee", "telecom" : [{ "system" : "url", "value" : "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee" }] } }, { "url" : "http://hl7.org/fhir/StructureDefinition/artifact-versionAlgorithm", "valueCoding" : { "system" : "http://hl7.org/fhir/version-algorithm", "code" : "semver", "display" : "SemVer" } }, { "url" : "http://hl7.org/fhir/StructureDefinition/resource-effectivePeriod", "valuePeriod" : { "start" : "2027" } }], "url" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ConceptMap/mii-cm-onko-atc-transitions-2024", "version" : "2027.0.0-ballot.1", "name" : "MII_CM_Onko_ATC_Transitions_2024", "title" : "MII CM Onko ATC Code Changes 2023 to 2024", "status" : "active", "experimental" : false, "date" : "2024-12-12", "publisher" : "Medizininformatik Initiative", "contact" : [{ "name" : "Medizininformatik Initiative", "telecom" : [{ "system" : "url", "value" : "https://www.medizininformatik-initiative.de/" }] }], "description" : "Diese ConceptMap dokumentiert die ATC-Code-Änderungen von 2023 zu 2024. Mehrere immunmodulatorische Substanzen wurden in neue Kategorien umklassifiziert, und Kombinationspräparate erhielten neue Codes.", "jurisdiction" : [{ "coding" : [{ "system" : "urn:iso:std:iso:3166", "code" : "DE", "display" : "Germany" }] }], "purpose" : "Migration von ATC-Codes für immunmodulatorische Substanzen und Kombinationspräparate, die 2024 umkodiert wurden.", "sourceCanonical" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2023", "targetCanonical" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2024", "group" : [{ "source" : "http://fhir.de/CodeSystem/bfarm/atc", "target" : "http://fhir.de/CodeSystem/bfarm/atc", "element" : [{ "code" : "L04AA34", "display" : "Alemtuzumab", "target" : [{ "code" : "L04AG06", "display" : "Alemtuzumab", "equivalence" : "equivalent", "comment" : "Reklassifizierung innerhalb der Immunsuppressiva" }] }, { "code" : "L04AA26", "display" : "Belimumab", "target" : [{ "code" : "L04AG04", "display" : "Belimumab", "equivalence" : "equivalent" }] }, { "code" : "L04AA25", "display" : "Eculizumab", "target" : [{ "code" : "L04AJ01", "display" : "Eculizumab", "equivalence" : "equivalent", "comment" : "Reklassifizierung zu Komplement-Inhibitoren" }] }, { "code" : "L04AA21", "display" : "Efalizumab", "target" : [{ "code" : "L04AG02", "display" : "Efalizumab", "equivalence" : "equivalent" }] }, { "code" : "L01EG02", "display" : "Everolimus", "target" : [{ "code" : "L04AH02", "display" : "Everolimus", "equivalence" : "equivalent", "comment" : "Zusätzliche Klassifizierung als Immunsuppressivum (behält auch L01EG02)" }] }, { "code" : "L04AA27", "display" : "Fingolimod", "target" : [{ "code" : "L04AE01", "display" : "Fingolimod", "equivalence" : "equivalent", "comment" : "Reklassifizierung zu Sphingosin-1-Phosphat-Rezeptor-Modulatoren" }] }, { "code" : "L04AA13", "display" : "Leflunomid", "target" : [{ "code" : "L04AK01", "display" : "Leflunomid", "equivalence" : "equivalent" }] }, { "code" : "L01FX24", "display" : "Mosunetuzumab", "target" : [{ "code" : "L01FX25", "display" : "Mosunetuzumab", "equivalence" : "equivalent", "comment" : "Code-Anpassung innerhalb der bispezifischen Antikörper" }] }, { "code" : "L04AA02", "display" : "Muromonab-CD3", "target" : [{ "code" : "L04AG01", "display" : "Muromonab-CD3", "equivalence" : "equivalent" }] }, { "code" : "L04AA23", "display" : "Natalizumab", "target" : [{ "code" : "L04AG03", "display" : "Natalizumab", "equivalence" : "equivalent" }] }, { "code" : "L01XY03", "display" : "Nivolumab und Relatlimab", "target" : [{ "code" : "L01FY02", "display" : "Nivolumab und Relatlimab", "equivalence" : "equivalent", "comment" : "Reklassifizierung zu Kombinationen monoklonaler Antikörper" }] }, { "code" : "L01FA02", "display" : "Ofatumumab", "target" : [{ "code" : "L04AG12", "display" : "Ofatumumab", "equivalence" : "equivalent", "comment" : "Zusätzliche Klassifizierung als Immunsuppressivum (behält auch L01FA02)" }] }, { "code" : "L01XY02", "display" : "Pertuzumab und Trastuzumab", "target" : [{ "code" : "L01FY01", "display" : "Pertuzumab und Trastuzumab", "equivalence" : "equivalent", "comment" : "Reklassifizierung zu Kombinationen monoklonaler Antikörper" }] }, { "code" : "L04AA10", "display" : "Sirolimus", "target" : [{ "code" : "L04AH01", "display" : "Sirolimus", "equivalence" : "equivalent", "comment" : "Reklassifizierung zu mTOR-Inhibitoren (Immunsuppressiva)" }] }] }] }